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to be established. We report our experience with a modiﬁed
infusion approach.
Between Nov 2010 and June 2013, 24 patients received rabbit
ATG for MUD allo-HSCT at our institution. From Nov 2010 -
Oct 2012 14 patients received protocol A with 2 mg/kg ATG
on days -4, -3, and -2 via titrated infusion over 4+ hrs with
methylprednisolone 60 mg IV and diphenhydramine 50 mg
PO prior to each ATG dose. From Oct 2012 - June 2013, 10
patients received protocol B whereby ATGwas over four days
(1mg/kg on day -5 and -2, 2mg/kg on days -4 and -3) at ﬁxed
rate over 20 hrs with no change to premedication; however,
additional diphenhydramine and famotidine were given
around the clock. For all patients, if ATG was held resulting in
wasting of partial dose, additional ATG was given to com-
plete total dose prescribed.
Over the course of ATG, the number of times the ATG infusion
was held due to an infusion reaction was higher for protocol
A (12 times for 14 patients) than protocol B (7 times for 10
patients). For the 14 patients on protocol A, 64% had ATG held
on day 1, 7% on day 2, and 14% on day 3. For the 10 patients on
protocol B, 20% had ATG held on day 1, 10% on day 2, and 20%
on days 3 and 4, respectively. Although the percent of pa-
tients experiencing fever, rigors, or tachycardia appeared to
be lower for protocol B on the ﬁrst two days of ATG, this was
not consistent for alterations in blood pressure or for the
third day of ATG infusion.
For each ATG day, additional doses of steroid were required
in more patients on protocol A vs. B (day one: 8 vs. 0; day
two: 2 vs. 0; day three: 5 vs. 1; day four: n/a vs. 0). The
median amount of additional steroid (in mg of methylpred-
nisolone equivalents) necessary in protocol A was 40 mg
(range 20-145) for the 8 patients treated on day one, 48 mg
(range 32-100) for the 3 patients on day two, and 80 mg
(range 30-125) for the 5 patients on day three. For protocol B,
only 1 patient required 30 mg of methylprednisolone on day
three.
No difference was noted in the number of patients who
required an additional amount of ATG to complete the
regimen (3/14 vs. 2/10). However, for protocol A the amount
of ATG administered on an additional day to complete the
regimen ranged from 11-33% of total ATG dose whereas for
protocol B the amount was 2.5-11% with one patient having
the amount added to the last day of scheduled ATG. Impor-
tantly, all patients successfully received the full amount of
ATG. No difference in time to engraftment was noted be-
tween groups.
This pilot data suggests slowing the infusion rate and
spreading the total ATG dose over 4 days with aggressive use
of antihistamine pre-medications has the potential to
decrease infusion reactions and need for additional steroid
doses. Additional patients on protocol B are being added and
results including long-term outcomes will be updated.Figure 2.449
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Stem cell mobilization and collection is a prerequisite for
ASCT. In 25-35% of patients, initial mobilization attempts fail
to harvest sufﬁcient peripheral blood stem cells (PBSC). The
standard practice was the addition of plerixafor to the
second mobilization attempt. A data-derived algorithm wasdeveloped to guide the use of plerixafor as a preemptive
strategy, at ﬁrst harvest, with the objective of preventing
ASCT delays, risk of disease progression, and reducing pa-
tient stress.
Patients and Methods: 25 patients were harvested for ASCT
in the ﬁrst year of implementation. The data-derived algo-
rithm identiﬁed patients likely to fail mobilization based on a
CD34+ cut-off for one or two ASCTs. Eight patients received
preemptive plerixafor and were compared to 6 patients who
received plerixafor as second line therapy in the previous
year.
Results: The average number of doses of ﬁlgrastim for the
second-line groupwas 16.5 vs 10.3 for the preemptive group,
a decrease of 38%. The doses of plerixafor and days of
apheresis were 2.33 vs 1.38 and 2.3 vs 1.6 for the second-line
vs the preemptive group (a 41% and 30% decrease for pre-
emptive). 83% of second-line patients proceeded to ASCT (1
progressed) vs 100% of preemptive patients at an average
number of days from ﬁrst harvest of 109 vs 47.7 days,
respectively. Engraftment was identical.
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required to harvest enough for one or two ASCTs is 10x106/L
and 2x106/L, respectively.
Conclusion: The algorithm has optimized the use of plerix-
afor. The number of doses of plerixafor and ﬁlgrastim, the
days of apheresis and the number of days to ASCT were all
reduced. A successful ﬁrst harvest attempt avoids transplant
delays, reduces the risk of interim disease progression,
avoids scheduling difﬁculties and reduces the stress to the
patient.450
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Background: Acute graft-versus-host disease (GVHD) re-
mains a leading complication in allogeneic hematopoietic
stem cell transplant (HSCT) recipients. Recently, our group
demonstrated a low rate of visceral acute GVHD with the
addition of maraviroc (MVC), a CCR5 antagonist, to tacroli-
mus (TAC) and methotrexate (MTX) in HSCT recipients(Reshef et al, NEJM 2012). MVC was initiated two days prior
to HSCT and continued until day +30. Limited data are
available regarding whether a pharmacokinetic interaction
exists between TAC and MVC, both CYP3A4 substrates. A
recent case report suggested an increase in TAC exposure
when combined with MVC in a liver transplant recipient
(Dufty et al, J Antimicrob Chemother 2013). We conducted a
retrospective analysis to evaluate whether a pharmacoki-
netic interaction exists between TAC and MVC in HSCT
recipients.
Methods: We retrospectively compared TAC concentrations
and concentration/dose ratios in 36 HSCT recipients
receiving GVHD prophylaxis with TAC/MTX/MVC with a
matched control population of 43 HSCT recipients receiving
TAC/MTX. Ratios were compared at 2 weeks and 6 weeks
following HSCT. Within group comparisons were made using
the Wilcoxon signed-rank test and between-group compar-
isons were analyzed using the Wilcoxon rank-sum test or
Student’s t-test as appropriate. A p-value of  0.05 was
considered signiﬁcant.
Results: The median TAC concentration/dose ratio in the
TAC/MTX/MVC group at week 2 was 2.8 (IQR 1.6 e 4.1) vs.
3.2 (IQR 2 to 4.2) in the TAC/MTX group (p¼0.31). At week 6
(2 weeks after MVC discontinuation), the median TAC
concentration/dose ratio increased in both groups, however
the within group changes were not signiﬁcant (TAC/MTX/
MVC week 2 vs. week 6: 2.8 vs. 3.1, p¼0.071; TAC/MTX
week 2 vs. week: 6 3.2 vs. 4.4, p¼0.077). Concentration/
dose ratios at week 6 were similar between groups: TAC/
MTX/MVC 3.1 (IQR 1.8 to 5.1) vs. TAC/MTX 4.4 (IQR 2.5 to
5.8), p¼0.1. Change from baseline was also similar between
groups: TAC/MTX/MVC 0.2 vs. TAC/MTX 0.5, p¼0.54. The
weekly mean TAC concentrations were similar between
groups at week 1: 11.1 ng/mL vs. 10.7 ng/mL; week 3: 10.1
ng/mL vs. 10.6 ng/mL; and week 4: 10.9 ng/mL vs. 11.8 ng/
mL; (p>0.05 for each week). At week 2, TAC levels were
lower in the TAC/MTX/MVC group (9.5 ng/mL vs. 11 ng/mL;
p¼0.045).
Conclusion: With the exception of week 2, we observed
no signiﬁcant differences in TAC concentrations or con-
centration/dose ratios over time in patients receiving
MVC compared to controls, implying that the protective
effect of maraviroc was not mediated through an increase
in TAC levels. However, the trend towards a decrease in
concentration/dose ratio of TAC upon discontinuation of
MVC suggests an inhibitory effect of MVC on TAC meta-
bolism. Further evaluation of this potential interaction in
larger studies is warranted and close monitoring of TAC
levels is required when the TAC and MVC are co-ad-
ministered.
